Fig. 4From: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in JapanProportion of patients with CRP level ≤ 0.02 mg/dl (post hoc analysis). CRP C-reactive protein, hs high-sensitivity, MTX methotrexate, q2w every 2 weeksBack to article page